Isomorphic Labs expands Novartis collaboration
Isomorphic Labs →Isomorphic Labs announced an agreement to expand its strategic research collaboration with Novartis, following the original collaboration announced in January 2024. The expansion added up to three additional research programs on the same financial terms as the original agreement. The company described the decision as reflecting progress in the first year of the collaboration. Novartis’s biomedical research leadership discussed exploring chemical space and challenging targets that could be difficult to address through traditional approaches. The announcement does not establish that all additional programs were initiated or that any contingent payments were earned. It concerns research collaboration scope rather than an equity investment or acquisition.